Please see full Prescribing Information for AREXVY. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

GSK's Arexvy shows strong immune response in adults aged 18-49 at risk for RSV-related respiratory disease. Over 21 million U.S. adults aged 18-49 may be at risk for RSV due to underlying conditions.

GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent ...

mResvia’s prescribing information indicates that the vaccine ... mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...

Talk to your doctor or visit www.AREXVY.com to learn more. Please see full Prescribing Information. You are encouraged to report vaccine adverse events to the US Department of Health and Human ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth. Sales of the jab for respiratory syncytial virus (RSV ...

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY(Respiratory ...